MYLIP Polyclonal Antibody, Biotin Conjugated
Applications
Reactivity
Predicted Reactivity
| Overview | |
| Catalog # | bs-9674R-Biotin |
| Product Name | MYLIP Polyclonal Antibody, Biotin Conjugated |
| Applications |
WB
IHC-P
|
| Reactivity | Human |
| Predicted Reactivity | Mouse, Rat, Dog, Cow, Pig, Horse, Rabbit |
| Specifications | |
| Conjugation | Biotin |
| Host | Rabbit |
| Source | KLH conjugated synthetic peptide derived from human MYLIP |
| Clonality | Polyclonal |
| Isotype | IgG |
| Concentration | 1ug/ul |
| Purification | Purified by Protein A. |
| Storage Buffer | Aqueous buffered solution containing 0.01M TBS (pH 7.4) with 1% BSA, 0.02% Proclin300 and 50% Glycerol. |
| Storage Condition | Store at -20C for 12 months. |
| Target | |
| Gene ID | 29116 |
| Swiss Prot | Q8WY64 |
| Subcellular location | Cell membrane |
| Synonyms | MIR; IDOL; E3 ubiquitin-protein ligase MYLIP; Inducible degrader of the LDL-receptor; Myosin regulatory light chain interacting protein; MYLIP; BZF1; BM-023; PP5242 |
| Background | E3 ubiquitin-protein ligase that mediates ubiquitination and subsequent proteasomal degradation of myosin regulatory light chain (MRLC), LDLR, VLDLR and LRP8. Activity depends on E2 enzymes of the UBE2D family. Proteasomal degradation of MRLC leads to inhibit neurite outgrowth in presence of NGF by counteracting the stabilization of MRLC by saposin-like protein (CNPY2/MSAP) and reducing CNPY2-stimulated neurite outgrowth. Acts as a sterol-dependent inhibitor of cellular cholesterol uptake by mediating ubiquitination and subsequent degradation of LDLR. |
| Application Dilution | |
| WB | 1:300-5000 |
| IHC-P | 1:200-400 |